OBJECTIVE: To determine whether warfarin-treated patients with an international normalized ratio less than 1.7 who receive intravenous tissue plasminogen activator for acute ischemic stroke are at increased risk for symptomatic intracerebral hemorrhage. DESIGN: Retrospective study. SETTING: Academic hospital. PATIENTS: Consecutive patients with acute ischemic stroke who are treated with intravenous tissue plasminogen activator. MAIN OUTCOME MEASURE: Symptomatic intracerebral hemorrhage. RESULTS: One hundred seven patients were included (mean age, 69.2 years; 43.9% men; median National Institutes of Health Stroke Scale score, 14; median onset-to-treatment time, 140 minutes; baseline warfarin use, 12.1%). The median international normalized ratio was 1.04 (range, 0.82-1.61). The overall rate of symptomatic intracerebral hemorrhage was 6.5%, but it was nearly 10-fold higher among patients taking warfarin compared with those not taking warfarin at baseline (30.8% vs 3.2%, respectively; P = .004). Baseline warfarin use remained strongly associated with symptomatic intracerebral hemorrhage (P = .004) after adjusting for relevant covariates, including age, atrial fibrillation, National Institutes of Health Stroke Scale score, and international normalized ratio. CONCLUSIONS: Despite an international normalized ratio less than 1.7, warfarin-treated patients are more likely than those not taking warfarin to experience symptomatic intracerebral hemorrhage following treatment with intravenous tissue plasminogen activator. Larger studies in this subgroup are warranted.
OBJECTIVE: To determine whether warfarin-treated patients with an international normalized ratio less than 1.7 who receive intravenous tissue plasminogen activator for acute ischemic stroke are at increased risk for symptomatic intracerebral hemorrhage. DESIGN: Retrospective study. SETTING: Academic hospital. PATIENTS: Consecutive patients with acute ischemic stroke who are treated with intravenous tissue plasminogen activator. MAIN OUTCOME MEASURE: Symptomatic intracerebral hemorrhage. RESULTS: One hundred seven patients were included (mean age, 69.2 years; 43.9% men; median National Institutes of Health Stroke Scale score, 14; median onset-to-treatment time, 140 minutes; baseline warfarin use, 12.1%). The median international normalized ratio was 1.04 (range, 0.82-1.61). The overall rate of symptomatic intracerebral hemorrhage was 6.5%, but it was nearly 10-fold higher among patients taking warfarin compared with those not taking warfarin at baseline (30.8% vs 3.2%, respectively; P = .004). Baseline warfarin use remained strongly associated with symptomatic intracerebral hemorrhage (P = .004) after adjusting for relevant covariates, including age, atrial fibrillation, National Institutes of Health Stroke Scale score, and international normalized ratio. CONCLUSIONS: Despite an international normalized ratio less than 1.7, warfarin-treated patients are more likely than those not taking warfarin to experience symptomatic intracerebral hemorrhage following treatment with intravenous tissue plasminogen activator. Larger studies in this subgroup are warranted.
Authors: Harsh R Aggarwal; Ameer E Hassan; Gustavo J Rodriguez; M Fareed K Suri; Robert A Taylor; Adnan I Qureshi Journal: J Vasc Interv Neurol Date: 2013-12
Authors: Felipe De Los Rios; Dawn O Kleindorfer; Amy Guzik; Santiago Ortega-Gutierrez; Navdeep Sangha; Gyanendra Kumar; James C Grotta; Jin-Moo Lee; Brett C Meyer; Lee H Schwamm; Pooja Khatri Journal: J Stroke Cerebrovasc Dis Date: 2014-08-10 Impact factor: 2.136
Authors: Tim Lekic; William Rolland; Richard Hartman; Joel Kamper; Hidenori Suzuki; Jiping Tang; John H Zhang Journal: Exp Neurol Date: 2010-09-29 Impact factor: 5.330
Authors: T Steiner; M Böhm; M Dichgans; H-C Diener; C Ell; M Endres; C Epple; M Grond; U Laufs; G Nickenig; H Riess; J Röther; P D Schellinger; M Spannagl; R Veltkamp Journal: Clin Res Cardiol Date: 2013-05-14 Impact factor: 5.460
Authors: Waltraud Pfeilschifter; Daniel Spitzer; Josef Pfeilschifter; Helmuth Steinmetz; Christian Foerch Journal: PLoS One Date: 2011-10-19 Impact factor: 3.240